US3755581036 - Common Stock
GILEAD SCIENCES INC
NASDAQ:GILD (7/26/2024, 7:00:01 PM)
After market: 76.9992 -0.01 (-0.01%)77.01
+0.5 (+0.65%)
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 18,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. The company is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The firm operates in more than 35 countries.
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA 94404
P: 16505743000
CEO: Daniel P. O'Day
Employees: 18000
Website: https://www.gilead.com/
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well.
Gilead Sciences Inc. is facing pressure to speed up its plans to bring an experimental HIV prevention drug to market after new data further underscored how useful the medicine could be in the fight against AIDS.
Here you can normally see the latest stock twits on GILD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: